In the 2016 finan­cial year, more than EUR 45 mil­lion flowed from the investor net­work of bm‑t beteili­gungs­man­age­ment thürin­gen gmbh (bm|t) into its inno­v­a­tive Thuringian port­fo­lio com­pa­nies. At around EUR 43 mil­lion, the major­ity was pro­vided by pri­vate domes­tic and for­eign investors, i.e. busi­ness angels, ven­ture cap­i­tal com­pa­nies or strate­gic investors.
The invested pri­vate cap­i­tal is dis­trib­uted among 17 Thuringian com­pa­nies, about half of which are in the start-up phase.
In addi­tion, bm|t also invested around EUR 17 mil­lion in these com­pa­nies itself through the funds it man­ages, so that a total of almost EUR 62 mil­lion flowed into inno­v­a­tive Thuringian companies.
This impres­sive num­ber of acquired pri­vate invest­ments not only rep­re­sents the high­est result since bm|t was founded in 2003, but is also proof of how attrac­tive and fast-grow­ing the cur­rently more than 40 inno­v­a­tive com­pa­nies in the bm|t port­fo­lio are for investors.
The largest sin­gle trans­ac­tion in 2016 was the financ­ing round of InflaRx GmbH, a bio­phar­ma­ceu­ti­cal com­pany from Jena.